SCHEMBL15030255

SCHEMBL15030255

Cc1cccn(CC(=O)c2ccc(F)c(F)c2)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.55
RXFP1 Q9HBX9 2/20 0.50
THRB P10828 1/20 0.50
MAPT P10636 2/20 0.49
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MMP8 P22894 1/20 0.46
MMP14 P50281 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
PKM P14618 1/20 0.45
ALOX12 P18054 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
ALPL P05186 2/20 0.39
ALPG P10696 2/20 0.39
ALPI P09923 1/20 0.39
PLAA Q9Y263 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16806635 0.93 THRB (0.52) POLBRXFP1THRBMAPTALDH1A1
SCHEMBL15030296 0.92 RXFP1 (0.50) POLBRXFP1THRBMAPTALDH1A1
SCHEMBL15030578 0.89 THRB (0.47) POLBRXFP1THRBMAPTALDH1A1
SCHEMBL15030487 0.87 ALDH1A1 (0.52) POLBRXFP1THRBMAPTALDH1A1
SCHEMBL15030298 0.87 RXFP1 (0.60) POLBRXFP1THRBMAPTALDH1A1
SCHEMBL15030414 0.86 PDE4B (0.49) POLBRXFP1THRBMAPTALDH1A1
SCHEMBL17677691 0.85 MMP14 (0.46) POLBRXFP1THRBMAPTALDH1A1
SCHEMBL15030528 0.85 THRB (0.49) POLBRXFP1THRBMAPTALDH1A1
SCHEMBL15030425 0.83 PKM (0.45) POLBRXFP1THRBMAPTALDH1A1
SCHEMBL16806629 0.82 KDM4E (0.54) POLBRXFP1THRBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3006437-B1 (+)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)-YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND DRUG CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2020-08-05 EP disclosed
US-10640484-B2 Method for producing (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and intermediate for producing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-05 US disclosed
US-20190276428-A1 METHOD FOR PRODUCING (R)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)-YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND INTERMEDIATE FOR PRODUCING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-09-12 US disclosed
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
US-9518041-B2 (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and drug containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-12-13 US disclosed
US-9518041-B2 (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and drug containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-12-13 US disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 US disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 US disclosed
US-9447072-B2 Pyridone derivative and pharmaceutical containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-09-20 US disclosed
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 US disclosed
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 US disclosed
US-20160130248-A1 (+)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)- YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND DRUG CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-05-12 US disclosed
US-20160130248-A1 (+)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)- YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND DRUG CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-05-12 US disclosed
EP-3006029-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION Kaken Pharmaceutical Co., Ltd. (JP) 2016-04-13 EP disclosed
EP-3006437-A1 (+)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)-YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND DRUG CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2016-04-13 EP disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
WO-2013085017-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 WO disclosed
WO-2013085016-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276428-A1 METHOD FOR PRODUCING (R)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)-YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND INTERMEDIATE FOR PRODUCING SAME DHPS, MRM1, PRMT5 POLB 1128/4885RXFP1 2426/4885THRB 2786/4885
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO POLB 3223/4885RXFP1 448/4885THRB 2444/4885
US-10640484-B2 Method for producing (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and intermediate for producing same DHPS, MRM1, PRMT5 POLB 1128/4885RXFP1 2426/4885THRB 2786/4885
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof PNPO, PDXK, PLPBP POLB 3715/4885RXFP1 296/4885THRB 2596/4885
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION PF4, F2, PFKP POLB 4128/4885RXFP1 460/4885THRB 2895/4885
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO POLB 3223/4885RXFP1 448/4885THRB 2444/4885
US-20160130248-A1 (+)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)- YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND DRUG CONTAINING SAME NOTUM, QDPR, GRIN2C POLB 3750/4885RXFP1 3654/4885THRB 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.